Citation profile for Amanda Megan Cole

Amanda Megan Cole : Citation Profile

Office of Health Economics

H index

i10 index

Citations

RESEARCH PRODUCTION:

Articles

Papers

RESEARCH ACTIVITY:

   6 years (2014 - 2020). See details.
   Cites by year: 1
   Journals where Amanda Megan Cole has often published
   Relations with other researchers
   Recent citing documents: 1.    Total self citations: 1 (9.09 %)

MORE DETAILS IN:

EconPapers ORCID profile

ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pco941
   Updated: 2024-11-04    RAS profile: 2022-02-10
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Towse, Adrian (2)

Zamora Talaya, Bernarda (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Amanda Megan Cole.

Is cited by:

Viney, Rosalie (2)

Shah, Koonal (1)

Devlin, Nancy (1)

Cites to:

Brazier, John (2)

Hole, Arne (2)

Claxton, Karl (2)

Shah, Koonal (1)

Karlsberg Schaffer, Sarah (1)

Yueh, Linda (1)

Viney, Rosalie (1)

Roberts, Jennifer (1)

Hinde, Sebastian (1)

Sculpher, Mark (1)

Towse, Adrian (1)

Main data

Where Amanda Megan Cole has published?

Journals with more than one article published	# docs
Applied Health Economics and Health Policy	2

Working Papers Series with more than one paper published	# docs
Briefing / Office of Health Economics	4

Recent works citing Amanda Megan Cole (2024 and 2023)

Year	Title of citing document
2023	Open and inclusive: fair processes for financing universal health coverage. (2023). Kurowski, Christoph. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:119795. Full description at Econpapers \|\| Download paper

Works by Amanda Megan Cole:

Year	Title	Type	Cited
2016	How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefing. [Full Text][Citation analysis]	paper	0
2016	“New Age” Decision Making in HTA: Is It Applicable in Asia? In: Briefing. [Full Text][Citation analysis]	paper	0
2019	Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? In: Briefing. [Full Text][Citation analysis]	paper	0
2019	Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? In: Briefing. [Full Text][Citation analysis]	paper	0
2014	Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP) In: Applied Health Economics and Health Policy. [Full Text][Citation analysis]	article	2
2017	A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis]	article	4
2018	Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment In: The European Journal of Health Economics. [Full Text][Citation analysis]	article	3
2020	Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value? In: The Patient: Patient-Centered Outcomes Research. [Full Text][Citation analysis]	article	1